Novel Pyridine Compounds
US-2024316020-A1 · Sep 26, 2024 · US
Pharmaceutical composition for oral administration
US2018116965A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2018116965-A1 |
| Application number | US-201615569682-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 27, 2016 |
| Priority date | Apr 28, 2015 |
| Publication date | May 3, 2018 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition for oral administration, the solubility and absorbability of the drug are improved.
First claim
Opening claim text (preview).
1 . A pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. 2 . The pharmaceutical composition for oral administration according to claim 1 , wherein the cellulose derivative is hydroxypropyl cellulose and/or hypromellose. 3 . The pharmaceutical composition for oral administration according to claim 1 , wherein the cellulose derivative is hydroxypropyl cellulose and/or hypromellose. 4 . The pharmaceutical composition for oral administration according to claim 1 , wherein 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, and a cellulose derivative form a solid dispersion. 5 . The pharmaceutical composition for oral administration according to claim 1 , further comprising an effervescent substance. 6 . The pharmaceutical composition for oral administration according to claim 5 , wherein the effervescent substance is sodium hydrogen carbonate. 7 . The pharmaceutical composition for oral administration according to claim 1 , further comprising a disintegrating component. 8 . The pharmaceutical composition for oral administration according to claim 7 , wherein the disintegrating component is one member or two or more members selected from the group consisting of crystalline cellulose, calcium hydrogen phosphate hydrate, sodium starch glycolate, low-substituted hydroxypropyl cellulose, and croscarmellose sodium. 9 . The pharmaceutical composition for oral administration according to claim 7 , wherein the disintegrating component is one member or two or more members selected from the group consisting of crystalline cellulose, low-substituted hydroxypropyl cellulose, and croscarmellose sodium. 10 . The pharmaceutical composition for oral administration according to claim 7 , wherein the disintegrating component is crystalline cellulose and/or croscarmellose sodium. 11 . The pharmaceutical composition for oral administration according to claim 7 , wherein the disintegrating component is croscarmellose sodium. 12 . The pharmaceutical composition for oral administration according to claim 1 , wherein the content of the cellulose derivative is 10% by weight to 1000% by weight with respect to the weight of 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof. 13 . The pharmaceutical composition for oral administration according to claim 1 , wherein the pharmaceutical composition for oral administration is a tablet. 14 . The pharmaceutical composition for oral administration according to claim 1 , wherein the pharmaceutical composition for oral administration is a pharmaceutical composition for preventing and/or treating bladder or urinary tract diseases related to bladder contraction by a muscarinic M3 receptor. 15 . (canceled)
Assignees
Inventors
Classifications
Effervescent (A61K9/0065 takes precedence) · CPC title
Inorganic compounds · CPC title
Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623) · CPC title
Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin · CPC title
Inorganic compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2018116965A1 cover?
- Disclosed is a pharmaceutical composition for oral administration, comprising 1-{5-[(5-{[(2R)-2-ethylpyrrolidin-1-yl]methyl}-4-[4-methoxy-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl)carbamoyl]pyrazin-2-yl}pyperidine-4-carboxylic acid, which is a compound having pH-dependent solubility, or a pharmaceutically acceptable salt thereof, and a cellulose derivative. In the pharmaceutical composition f…
- Who is the assignee on this patent?
- Astellas Pharma Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K9/2054. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu May 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).